Two Big Tech Moves That Caught Our Eye This Week, and Gilead Gets on the GLP-1 Train 6/14/24
CNBC's "Fast Money"
00:00
A Look at Gilead's New GLP-1 Drug and Stock Market Updates
Exploring Gilead's new entry into the GLP-1 space with promising weight loss results, alongside insights on Bitcoin's performance and stock market updates including cruise stocks, Adobe, and more. Also, Senator Sanders reveals Novo Nordisk's CEO will testify on GLP1 drug costs before a Senate committee.
Play episode from 27:57
Transcript
